October 7, 2019
US Merck submitted its PD-1 inhibitor Keytruda (pembrolizumab) for an additional indication of unresectable, advanced/relapsed gastric cancer in Japan on October 4, the company’s local arm said the same day. The filing is based on data from a global PIII...read more